Further clinical sample analyses have revealed higher levels of the glutaminolysis-related genes expression, including GLUD1 and GLS1, and positive GLUD1 and GLS1 protein expression are significantly associated with shorter clinical outcome in the prostate cancers. This evidence concerns the gene GLUD1 and prostate cancer.